Oncogenic rearrangements of the ALK receptor tyrosine kinase (ALK) gene are detected in approximately 7% of NSCLC patients.1 However, novel partner genes for ALK fusion and their clinical significance are not fully defined. Herein we describe the first case of ALK fusion with the myosin phosphatase Rho interacting protein gene (MPRIP) via next-generation sequencing (NGS), whose oncogenicity was further validated in vitro. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.02.030
Authors: Wenfeng Fang, Jiadi Gan, Shaodong Hong, Feng Lu, Li Zhang.